ReviewCurrent rheumatology reports2012
The rationale for BAFF inhibition in systemic lupus erythematosus.
Review in Current rheumatology reports, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 45 citations in OpenAlex.
- Belimumab in Systemic Lupus Erythematosus: From B-Cell Biology to Disease Modification.Journal of clinical medicine · 2026Review
- Restoring B cell intrinsic tolerance to lupus autoimmunity: a rational strategy for lupus treatment.Frontiers in immunology · 2026Review
- Serum levels of APRIL, BAFF, and IL-10 in systemic lupus erythematosus have limited utility as biomarkers for disease activity or flare prediction.Clinical rheumatology · 2026Article
- Severe pulmonary arterial hypertension development despite lupus nephritis remission: association with podocytic infolding glomerulopathy.BMC nephrology · 2025Article
- Immune metabolic restoration in systemic lupus erythematosus: the impact of gut microbiota, probiotics, and nutritional synergy.Frontiers in immunology · 2025Review
- Integrative miRNA-mRNA profiling uncovers mechanisms of belimumab action in systemic lupus erythematosus.Frontiers in immunology · 2025Article
- Sequential immunotherapy: towards cures for autoimmunity.Nature reviews. Drug discovery · 2024Review
- A novel selective spleen tyrosine kinase inhibitor SKI-O-703 (cevidoplenib) ameliorates lupus nephritis and serum-induced arthritis in murine models.Clinical and experimental immunology · 2023Article
- Dysregulated MicroRNAs in the Pathogenesis of Systemic Lupus Erythematosus: A Comprehensive Review.International journal of biological sciences · 2023Review
- Belimumab for systemic lupus erythematosus - Focus on lupus nephritis.Human vaccines & immunotherapeutics · 2022Review
- Recent Advances in Understanding the Pathogenesis of Rheumatoid Arthritis: New Treatment Strategies.Cells · 2021Review
- The gene silencing of IRF5 and BLYSS effectively modulates the outcome of experimental lupus nephritis.Molecular therapy. Nucleic acids · 2021Article
- An update on lupus animal models.Current opinion in rheumatology · 2017Review
- Article
- BANK1 Regulates IgG Production in a Lupus Model by Controlling TLR7-Dependent STAT1 Activation.PloS one · 2016Article
- Article
- IFN-gamma AU-rich element removal promotes chronic IFN-gamma expression and autoimmunity in mice.Journal of autoimmunity · 2014Article
- Cellular signaling and production of galactose-deficient IgA1 in IgA nephropathy, an autoimmune disease.Journal of immunology research · 2014Review
- Neutrophils contribute to excess serum BAFF levels and promote CD4+ T cell and B cell responses in lupus-prone mice.PloS one · 2014Article
- Treatment of systemic lupus erythematosus: new therapeutic avenues and blind alleys.Nature reviews. Rheumatology · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
BAFF (B-cell-activating factor) is a critical survival factor for transitional and mature B cells and is a promising therapeutic target for systemic lupus erythematosus (SLE). In 2010-2011, two phase 3 clinical trials showed that the addition of the anti-BAFF antibody belimumab to standard-of-care therapy in patients with moderately active SLE results in a better outcome at 52 weeks than standard-of-care therapy alone. Belimumab has been US Food and Drug Administration approved for the treatment of SLE, and other drugs that target BAFF are now in various stages of clinical testing. This review describes the function of BAFF and its homolog APRIL (a proliferation-inducing ligand) and addresses the rationale for the treatment of SLE with BAFF/APRIL inhibitors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.